Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. contitrace

ContiTRACE SIGNED

Continuous Blood Glucose Monitoring and automated therapeutic closed loop medical device for Intensive Care Units

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ContiTRACE project word cloud

Explore the words cloud of the ContiTRACE project. It provides you a very rough idea of what is the project "ContiTRACE" about.

business    diagnostica    glucose    safe    offline    patient    safety    decisions    blood    accesses    contitrace    comorbidities    roche    50    units    icu    big    40    infusion    careful    savings    ai    irregular    max    return    profil    commercial    pharma    care    economic    human    intensive    estimates    body    aventis    device    icus    adjustments    sensors    made    minimising    sasse    self    days    physiological    workload    time    automatically    fluctuations    insulin    limited    minutes    players    calibrating    informed    medical    private    hospital    costly    consumables    sell    forecast    company    samples    model    proves    300    distributors    manual    patented    automated    mortality    inefficient    twofold    elektronik    keep    powered    2022    levels    bgm    material    sanofi    doctors    intermittent    regulatory    discomfort    technique    risk    monitoring    caregivers    companies    2026    healthcare    17    5th    optimize    lifecycle    patients    increments    headcounts    manufacturers    infuse    profits    glycaemic    newcomers    invasive    pfizer    penetrate    death    14    continuous    investment    standardized    decrease    public    x10    15    trace   

Project "ContiTRACE" data sheet

The following table provides information about the project.

Coordinator		 TRACE ANALYTICS GMBH 

Organization address
address: RICHARD WAGNER STRASSE 1-2
city: BRAUNSCHWEIG
postcode: 38106
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRACE ANALYTICS GMBH DE (BRAUNSCHWEIG) coordinator 50˙000.00

Map

 Project objective

Intensive Care Units (ICUs) require careful monitoring of blood glucose levels and insulin infusion to keep patients within safe physiological levels. Fluctuations of blood glucose are directly related to an increased risk of death and comorbidities. However, blood glucose monitoring (BGM) is still made by intermittent and manual offline analysis of blood samples. This technique proves inefficient (need 17% caregivers time), costly (€300 per patient) and increments mortality in hospital ICUs by 40% due to irregular glucose level adjustments upon measurements. After 15 years of experience in developing glucose monitoring sensors, we at TRACE are taking on our next big step to penetrate the medical device sector with ContiTRACE: an AI powered automated non-invasive medical device for continuous BGM. Our patented ContiTRACE is able to measure glycaemic levels every 2 minutes (automatically) and automatically infuse insulin when needed. It is also capable of self-calibrating and has standardized body accesses, enhancing safety and minimising discomfort for the ICU patient. This will allow 1) caregivers to decrease their workload, 2) doctors to take informed decisions and 3) the healthcare system to optimize their limited human, economic and material resources by providing savings of more than 50% of BGM related cost. Our business model is twofold. We will sell the medical device (5 years lifecycle), and the consumables (max. 4 days duration per set) to private and public hospital ICUs. Our draft forecast (2022-2026) estimates profits of 14.4 M€ with a Return on Investment of 10.7 by the 5th commercial year allowing us to increase x10 our company headcounts in five commercial years. Although newcomers to the medical sector we have the support of key players among regulatory companies (Profil), manufacturers (Sasse Elektronik), pharma companies (Sanofi-Aventis, Pfizer and Roche) and distributors (Care Diagnostica) to take on the BGM challenge.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONTITRACE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONTITRACE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

COUNTMITMENT (2019)

NATURAL CAPITAL ACCOUNTANCY TO IMPROVE REPORTING AND ENVIRONMENTAL PERFORMANCE

Read More  

EVERCAM (2020)

Intelligent Vision System for Improved Communication and Higher Productivity in Construction

Read More